Wed, Dec 17, 2014, 5:28 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

NPS Pharmaceuticals, Inc. Message Board

  • krnfreak99 krnfreak99 Oct 12, 2012 1:39 PM Flag

    Hold through panel vote?

    Thoughts? I'm not concerned about it being rejected, but I'm curious how much is priced in at this point. I have seen numerous stocks sell off with actual FDA approval, but I'm not so sure about panel votes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't think the panel vote is fully priced in. The peak revenue for Gattex can reach $350M excluding off-label uses. Multiply this with 5 you get a $1.75B market value. Gattex is now a slam dunk. Natpara is also a high possibility.

      Based on most conservative predictions:

      - Gattex approved
      - no off-label use
      - Natpara rejected

      NPSP should still be a $1.75B company. This converts to about $20 per share. MM can manipulate this stock after panel vote just to buy cheap but this may be a $20 stock by year end.

      Sentiment: Buy

    • 11000 shares at average of 6,47. Expect to hold for 2 more years. Looking for $35 +. GLTA

      Sentiment: Strong Buy

36.10+5.63(+18.48%)Dec 17 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.